ADC Therapeutics SA Interest Received Classified As Operating Activities
ADC Therapeutics SA (ADCT) reported Interest Received Classified As Operating Activities of $7.87 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
ifrs-full:InterestReceivedClassifiedAsOperatingActivities · last filed 2023-11-07
- ADC Therapeutics SA interest received classified as operating activities for the quarter ending 2023-09-30 was $2.70M, a 889.74% increase year-over-year.
- ADC Therapeutics SA interest received classified as operating activities for the quarter ending 2023-06-30 was $2.37M, a 13077.78% increase year-over-year.
- ADC Therapeutics SA interest received classified as operating activities for the quarter ending 2023-03-31 was $2.79M, a 15427.78% increase year-over-year.
- ADC Therapeutics SA interest received classified as operating activities for the quarter ending 2022-12-31 was $1.64M, a 8095.00% increase year-over-year.
| Period end | Interest Received Classified As Operating Activities 3 month | Interest Received Classified As Operating Activities 6 month | Interest Received Classified As Operating Activities 9 month | Interest Received Classified As Operating Activities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.70M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $5.07M derived: sum of 2 quarters · filed 2023-11-07 | $7.87M 6-K · filed 2023-11-07 | $9.51M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $2.37M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $5.17M 6-K · filed 2023-08-08 | $6.81M derived: sum of 3 quarters · filed 2023-08-08 | $7.08M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $2.79M 6-K · filed 2023-05-09 | $4.43M derived: sum of 2 quarters · filed 2023-05-09 | $4.71M derived: sum of 3 quarters · filed 2023-11-07 | $4.72M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $1.64M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $1.91M derived: sum of 2 quarters · filed 2023-11-07 | $1.93M derived: sum of 3 quarters · filed 2023-11-07 | $1.95M 20-F · filed 2023-03-15 |
| 2022-09-30 | $273.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $291.00K derived: sum of 2 quarters · filed 2023-11-07 | $309.00K 6-K · filed 2023-11-07 | $329.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $18.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $36.00K 6-K · filed 2023-08-08 | $56.00K derived: sum of 3 quarters · filed 2023-08-08 | $70.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $18.00K 6-K · filed 2023-05-09 | $38.00K derived: sum of 2 quarters · filed 2023-05-09 | $52.00K derived: sum of 3 quarters · filed 2023-05-09 | $58.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $20.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $34.00K derived: sum of 2 quarters · filed 2023-03-15 | $40.00K derived: sum of 3 quarters · filed 2023-03-15 | $56.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | $14.00K derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $20.00K derived: sum of 2 quarters · filed 2022-11-08 | $36.00K 6-K · filed 2022-11-08 | $86.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $6.00K derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $22.00K 6-K · filed 2022-08-09 | $72.00K derived: sum of 3 quarters · filed 2023-03-15 | $231.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $16.00K 6-K · filed 2022-05-09 | $66.00K derived: sum of 2 quarters · filed 2023-03-15 | $225.00K derived: sum of 3 quarters · filed 2023-03-15 | $439.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $50.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $209.00K derived: sum of 2 quarters · filed 2023-03-15 | $423.00K derived: sum of 3 quarters · filed 2023-03-15 | $797.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | $159.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $373.00K derived: sum of 2 quarters · filed 2021-11-02 | $747.00K 6-K · filed 2021-11-02 | |
| 2020-06-30 | $214.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $588.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $374.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $1.16M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $1.05M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |